BioDelivery Sciences (BDSI) Misses Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to BioDelivery Sciences (BDSI) Misses Q4 EPS by 3c

BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results

March 17, 2017 6:30 AM EDT

RALEIGH, N.C., March 17, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the fourth quarter and full year ended December 31, 2016, and provided an update on recent business highlights and upcoming milestones.

In January 2017, BDSI reacquired worldwide rights to BELBUCA® (buprenorphine) buccal film (CIII) from Endo Pharmaceuticals.  The transfer of worldwide rights back to BDSI followed a strategic decision announced by Endo in December 2016 to discontinue commercial efforts for the U.S. branded pain business.  Based on the agreement, BDSI will... More